Docoh
Loading...

AERI Aerie Pharmaceuticals

Employees

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

ESG term mentions

In last year of SEC filings
BiodegradableCarbon NeutralClimateClimate ChangeConservationEnvironmentEnvironmentalEnvironmental ProtectionGreenHazardIntensityLEEDLow-Carbon EconomyMaterialsNatureOffsetPackagePackagingPandemicPlasticRaw MaterialsRecycledRecyclingRegenerativeRenewableSolarWasteWaterWindAccessAffordabilityAsianBenefitsBlackCharitableCitizenshipCollective BargainingCommunityCultureCustomerCyberCyber SecurityCybersecurityData PrivacyData SecurityDeathDemographicDisabilityDiversityDiversity and InclusionDrug PricingEmployeeEmployee RetentionEngagementEthnicEthnicityGeneral Data Protection RegulationHealth and SafetyHealth CareHealthcareHireHiringHispanicHuman CapitalHuman ResourcesIncidentIncident rateInjuryMinorityOSHAPaid Sick LeavePay EquityPay for PerformancePerquisitesPhilanthropicPrivacyProduct SafetyRecallRecruitRecruitmentReimbursementRetentionRetirementSafetySatisfactionSkillSkilledSkillsSocialSocietyStakeholderSupplierSupply ChainTalentTrainingUnionVolunteerWomenWorkersWorkforceWorking ConditionAction PlanAnti-corruptionAssessmentAssuranceAttorneys GeneralAuditBonusBriberyChronicClass Action LawsuitClassifiedClassified BoardClaw BackCommitmentCorporate GovernanceCorporate PurposeDepartment ofESGEthicsExecutive CompensationExpertFraudGoalsGovernanceHedgingIncentiveIndependenceIndependentInnovationInnovativeInvestigationLawsuitLead Independent DirectorLeadershipLitigationLong-termMajorityOther Public Company BoardsOverseeOversightPerquisitePledgingProcurementPurposeQuality StandardR&DRecoupReputationReputationalResearch and DevelopmentResponsibilityResponsibleSelf-evaluationSpecial MeetingStewardshipStockholder EngagementStrategySustainabilitySustainableTargetsTaxTenureTransparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
At the 2021 Annual Meeting of Stockholders of Aerie Pharmaceuticals, Inc. (the “Company”), held on June 17, 2021, the Company’s stockholders considered and voted upon the following proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2021:

Proposal 1: Elections of Directors.


By vote reflected below, each of the following director nominees was elected to serve on the Board of Directors for a three-year term, or until his successor has been duly elected and qualified.

NomineeVotes ForVotes
Withheld
Broker Non-Votes
Mechiel (Michael) M. du Toit27,716,1886,163,9723,476,747
David W. Gryska33,075,157805,0033,476,747


Proposal 2:Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.


By vote reflected below, the appointment of PricewaterhouseCoopers LLP was ratified.

Votes ForVotes AgainstVotes Abstained
36,977,984356,71122,212


Proposal 3: To approve, by a non-binding vote, the compensation of the Company’s named executive officers (“say-on-pay”).


By vote reflected below, the Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.

Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
19,277,87914,399,168203,1133,476,747